苏木酚 | 111254-19-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 高异黄酮
• 中文名称: 苏木酚
• 英文名称: (3RS,4SR)-3-(3,4-dihydroxybenzyl)-3,4,7-trihydroxychroman <(+/-)-sappanol>
• 英文别名: (3RS,4SR)-3-(3,4-dihydroxybenzyl)-3,4,7-trihydroxychroman ((+/-)-sappanol)；Sappanol；(3R,4S)-3-[(3,4-dihydroxyphenyl)methyl]-2,4-dihydrochromene-3,4,7-triol
• CAS: 111254-19-4
• 化学式: C₁₆H₁₆O₆
• 分子量: 304.299
• InChiKey: MPGFEHZDABUJFR-JKSUJKDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  苏木酚 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以23 mg的产率得到(+)-(6ar,11bc)-7,11b-dihydro-indeno[2,1-c]chromene-3,6a,9,10-tetraol
  参考文献：
  名称：

  Homoisoflavonoids and related compounds. II. Isolation and absolute configurations of 3,4-dihydroxylated homoisoflavans and brazilins from Caesalpinia sappan L.

  摘要：

  从蓝花楹（Caesalpinia sappan）的干燥心材 Sappan Lignum 中分离出了三种新的酚类化合物，即 3'-Ο-methylsappanol 、3'-Ο-methylpyleisappanol 和 3'-Ο-methylbrazilin 。通过 Horeau 部分解析法和化学相关性测定了山梨醇、表山梨醇、3'-脱氧山梨醇、3'-Ο-甲基山梨醇、3'-Ο-甲基甲基山梨醇、巴西苷和 3'Ο-methylbrazilin 的绝对构型。萨帕醇、表萨帕醇、3'-脱氧萨帕醇、3'-Ο-甲基萨帕醇和 3'-Ο-methylepisappanol 形成了一类新的同异黄酮化合物。

  DOI：

  10.1248/cpb.35.2761
• 作为产物：
  描述：

  Sappanone A 在 palladium on activated charcoal sodium hydroxide 、 lithium aluminium tetrahydride 、 氢气 、 双氧水 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 30.0h， 生成 苏木酚
  参考文献：
  名称：

  Homoisoflavonoids and related compounds. II. Isolation and absolute configurations of 3,4-dihydroxylated homoisoflavans and brazilins from Caesalpinia sappan L.

  摘要：

  从蓝花楹（Caesalpinia sappan）的干燥心材 Sappan Lignum 中分离出了三种新的酚类化合物，即 3'-Ο-methylsappanol 、3'-Ο-methylpyleisappanol 和 3'-Ο-methylbrazilin 。通过 Horeau 部分解析法和化学相关性测定了山梨醇、表山梨醇、3'-脱氧山梨醇、3'-Ο-甲基山梨醇、3'-Ο-甲基甲基山梨醇、巴西苷和 3'Ο-methylbrazilin 的绝对构型。萨帕醇、表萨帕醇、3'-脱氧萨帕醇、3'-Ο-甲基萨帕醇和 3'-Ο-methylepisappanol 形成了一类新的同异黄酮化合物。

  DOI：

  10.1248/cpb.35.2761

文献信息

• NAMIKOSHI, MICHIO;NAKATA, HIROYUKI;YAMADA, HIROYUKI;NAGAI, MINAKO;SAITOH,+, CHEM. AND PHARM. BULL., 35,(1987) N 7, 2761-2773
  作者：NAMIKOSHI, MICHIO、NAKATA, HIROYUKI、YAMADA, HIROYUKI、NAGAI, MINAKO、SAITOH,+

  DOI：——

  日期：——
• REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF
  申请人：RATAN Rajiv

  公开号：US20130005666A1

  公开（公告）日：2013-01-03

  The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
• US9200046B2
  申请人：——

  公开号：US9200046B2

  公开（公告）日：2015-12-01
• [EN] COMPOSITION FOR PREVENTING AND TREATING PROSTATE CANCER CONTAINING CAESALPINIA SAPPAN L. EXTRACT<br/>[FR] COMPOSITION CONTENANT DE L'EXTRAIT DE CAESALPINIA SAPPAN L. POUR PRÉVENIR ET TRAITER LE CANCER DE LA PROSTATE
  申请人：KOREA BIO MEDICAL SCIENCE INST

  公开号：WO2012030149A2

  公开（公告）日：2012-03-08

  본 발명은 소목 추출물의 신규한 용도에 관한 것에 관한 것으로서, 보다 상세하게는 소목 유기용매 추출물을 유효성분으로 함유하는 전립선암 예방 및 치료용 조성물에 관한 것이다. 본 발명에 따른 전립선암 치료용 조성물은 전립선암 세포의 성장을 억제하고 세포사멸을 유도하는 효과가 있어 전립선암 치료 및 예방에 효과적으로 사용할 수 있다.
• [EN] METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES<br/>[FR] PROCÉDÉS LIÉS À DES AGENTS BIOACTIFS QUI CONVERTISSENT DES ANIONS EN MOLÉCULES
  申请人：NATURAL EXTRACTION SYS LLC

  公开号：WO2021158573A1

  公开（公告）日：2021-08-12

  Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administration to a subject. Such compositions display improved bioavailability and pharmacokinetics relative to compositions that comprise the hydrophobic bioactive molecules instead of the anions.